PARP16

Across TCGA pan-cancer cohorts, PARP16 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of PARP16’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where PARP16 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types PARP16 is over-expressed in tumor, although a few such as COAD and HNSC show the opposite, repressed pattern.

LSCC, CCRCC, and COAD are the cancer types where PARP16 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PARP16 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LSCC	All	II,III,IV	+0.188	<.001	8	view →
CCRCC	All	All	+0.170	.005	4	view →
COAD	Male	All	−0.925	.031	2	view →
PDAC	All	IV	+0.465	.020	1	view →
HNSC	Male	IV	−0.249	.040	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

PARP16–LSCC

Open the LSCC breakdown →